Plano-based Integer Holdings Corp.—a leading medical device contract development and manufacturing organization—announced that Chief Operating Officer Payman Khales will assume the roles of president and CEO position and join the company’s board, effective Oct. 24.

He will succeed Joseph Dziedzic, who will retire as president and CEO and will step down from the board of directors on that date.

“We’re incredibly grateful to Joe, whose vision, strategy, and ability to create a high-performance culture has driven Integer’s significant growth and value creation during his eight-year tenure as CEO,” Board Chair Pamela G. Bailey said in a statement. “Among many other accomplishments, Joe reshaped Integer’s business to focus on high growth markets that address unmet patient needs, accelerated organic and inorganic investment in differentiated technologies, and developed and implemented the Integer Production System to create consistency across our manufacturing operations.”

Bailey wished Dziedzic “the very best in a well-deserved retirement.”  

She added, “Integer is delivering on its financial objectives of above market organic sales growth with expanding margins and is well positioned to continue this growth trajectory.”

Integer said that to ensure a smooth transition, Dziedzic will serve as an adviser to the company through March 31, 2026.

“It has been an honor to lead the Integer team through this pivotal period in our company’s history, and I’m proud of what we have accomplished for our customers and patients around the world,” Dziedzic said in a statement.

He noted that Khales is the right leader to “guide Integer through our next chapter of growth.”

“He is an exceptional leader who embodies our commitment to innovation, quality and operational excellence, and his track record speaks for itself,” Dziedzic said. “Payman has been an integral part of the development and execution of our strategy, both within Cardio & Vascular and across the enterprise, while leading Integer’s Customer Operational Strategic Imperatives. I look forward to the company’s continued success under Payman’s leadership.”

Growth and strategic innovation

Khales joined Integer in 2018 as president of its Cardio & Vascular business.

The company said under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth, while improving service levels and profitability.

Integer said that since becoming COO, Khales has overseen both of Integer’s business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy.

“I’m honored to be named the next CEO of Integer and would like to thank Joe and the board of directors for having faith in me to lead this amazing company in its next chapter,” Khales said in a statement. “I’m excited about the strong momentum in our business as we continue to build differentiated capabilities and collaborate closely with our customers to deliver innovative medical device technologies to patients around the globe.”

Khales praised the leadership of his predecessor.

“I thank Joe for his mentorship over the past seven years and continued support in the coming months as we prepare to transition,” he said. “He set the vision and strategy that transformed Integer into the strong company it is today, and I wish him a very enjoyable retirement later this year.”

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.